<DOC>
	<DOC>NCT02970942</DOC>
	<brief_summary>Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis</brief_summary>
	<brief_title>Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Informed consent obtained before any trialrelated activities.Trialrelated activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial Male or female, aged 1875 years (both inclusive) (for Japan: male or female aged 2075 years (both inclusive)) at the time of signing informed consent Local histological diagnosis of NASH followed by histological confirmation of NASH based on central pathologist evaluation of a liver biopsy obtained up to 21 weeks before screening A histological NAS equal or above 4 with a score of 1 or more in each subcomponent of the score based on central pathologist evaluation NASH fibrosis stage 2 or 3 according to the NASH CRN fibrosis staging system based on central pathologist evaluation Known or suspected abuse of alcohol (above 20 g/day for women or above 30 g/day for men), alcohol dependence* or narcotics. (* = assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)) Diagnosis of type 1 diabetes according to medical records HbA1c above 9% at screening History or presence of pancreatitis (acute or chronic) Calcitonin equal or above 50 ng/L at screening Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. Family is defined as a first degree relative Body Mass Index (BMI) equal or below 25.0 or equal or above 45.0 kg/m^2 at the screening visit Female who is pregnant, breastfeeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>